Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development... Show more
The Moving Average Convergence Divergence (MACD) for LTRN turned positive on June 24, 2025. Looking at past instances where LTRN's MACD turned positive, the stock continued to rise in of 54 cases over the following month. The odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on July 08, 2025. You may want to consider a long position or call options on LTRN as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
LTRN moved above its 50-day moving average on July 10, 2025 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for LTRN crossed bullishly above the 50-day moving average on July 15, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LTRN advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for LTRN moved out of overbought territory on July 18, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 22 similar instances where the indicator moved out of overbought territory. In of the 22 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
LTRN broke above its upper Bollinger Band on July 17, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.565) is normal, around the industry mean (18.109). P/E Ratio (0.000) is within average values for comparable stocks, (58.647). LTRN's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.460). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (270.773).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LTRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LTRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data
Industry Biotechnology